nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—TEC—lymphoid tissue—pharynx cancer	0.00556	0.0103	CbGeAlD
Dasatinib—MYT1—head—pharynx cancer	0.00527	0.00972	CbGeAlD
Dasatinib—EPHB2—brainstem—pharynx cancer	0.00522	0.00964	CbGeAlD
Dasatinib—PTK6—saliva-secreting gland—pharynx cancer	0.00511	0.00943	CbGeAlD
Dasatinib—LIMK2—mouth—pharynx cancer	0.0051	0.0094	CbGeAlD
Dasatinib—BMX—epithelium—pharynx cancer	0.00476	0.00878	CbGeAlD
Dasatinib—STAT5B—brainstem—pharynx cancer	0.00474	0.00874	CbGeAlD
Dasatinib—SIK1—mouth—pharynx cancer	0.00445	0.0082	CbGeAlD
Dasatinib—EPHA4—mouth—pharynx cancer	0.0044	0.00812	CbGeAlD
Dasatinib—ERBB3—mouth—pharynx cancer	0.00436	0.00804	CbGeAlD
Dasatinib—STAT5B—epithelium—pharynx cancer	0.00422	0.00778	CbGeAlD
Dasatinib—MAPK14—mouth—pharynx cancer	0.00406	0.00749	CbGeAlD
Dasatinib—PTK6—trachea—pharynx cancer	0.00394	0.00727	CbGeAlD
Dasatinib—FRK—lymphoid tissue—pharynx cancer	0.00375	0.00693	CbGeAlD
Dasatinib—TESK1—parotid gland—pharynx cancer	0.00373	0.00688	CbGeAlD
Dasatinib—BLK—lymphoid tissue—pharynx cancer	0.00362	0.00668	CbGeAlD
Dasatinib—EPHB2—lymphoid tissue—pharynx cancer	0.00358	0.00661	CbGeAlD
Dasatinib—TESK1—saliva-secreting gland—pharynx cancer	0.00357	0.00659	CbGeAlD
Dasatinib—EPHB3—saliva-secreting gland—pharynx cancer	0.00351	0.00649	CbGeAlD
Dasatinib—EPHB1—head—pharynx cancer	0.00351	0.00648	CbGeAlD
Dasatinib—MAPK14—neck—pharynx cancer	0.00347	0.0064	CbGeAlD
Dasatinib—TXK—lymphoid tissue—pharynx cancer	0.00347	0.0064	CbGeAlD
Dasatinib—EPHB3—brainstem—pharynx cancer	0.00344	0.00635	CbGeAlD
Dasatinib—CSK—parotid gland—pharynx cancer	0.00342	0.0063	CbGeAlD
Dasatinib—BMPR1B—epithelium—pharynx cancer	0.00338	0.00623	CbGeAlD
Dasatinib—CSK—saliva-secreting gland—pharynx cancer	0.00327	0.00604	CbGeAlD
Dasatinib—STAT5B—lymphoid tissue—pharynx cancer	0.00325	0.00599	CbGeAlD
Dasatinib—STK35—brainstem—pharynx cancer	0.00323	0.00595	CbGeAlD
Dasatinib—RIPK2—parotid gland—pharynx cancer	0.00317	0.00585	CbGeAlD
Dasatinib—TEC—lymph node—pharynx cancer	0.00314	0.00579	CbGeAlD
Dasatinib—SIK2—head—pharynx cancer	0.0031	0.00573	CbGeAlD
Dasatinib—SIK1—parotid gland—pharynx cancer	0.0031	0.00571	CbGeAlD
Dasatinib—RIPK2—saliva-secreting gland—pharynx cancer	0.00304	0.0056	CbGeAlD
Dasatinib—PKMYT1—head—pharynx cancer	0.00303	0.00558	CbGeAlD
Dasatinib—SIK1—saliva-secreting gland—pharynx cancer	0.00297	0.00547	CbGeAlD
Dasatinib—ERBB3—saliva-secreting gland—pharynx cancer	0.00291	0.00536	CbGeAlD
Dasatinib—EPHB2—head—pharynx cancer	0.00289	0.00533	CbGeAlD
Dasatinib—EPHA4—brainstem—pharynx cancer	0.00288	0.00531	CbGeAlD
Dasatinib—SRMS—head—pharynx cancer	0.00282	0.00521	CbGeAlD
Dasatinib—TXK—head—pharynx cancer	0.0028	0.00516	CbGeAlD
Dasatinib—EPHA8—head—pharynx cancer	0.00277	0.00511	CbGeAlD
Dasatinib—TESK1—trachea—pharynx cancer	0.00276	0.00508	CbGeAlD
Dasatinib—FMO3—parotid gland—pharynx cancer	0.00272	0.00502	CbGeAlD
Dasatinib—ZAK—lymphoid tissue—pharynx cancer	0.00271	0.00501	CbGeAlD
Dasatinib—STK36—trachea—pharynx cancer	0.00271	0.005	CbGeAlD
Dasatinib—EPHB3—trachea—pharynx cancer	0.00271	0.005	CbGeAlD
Dasatinib—EPHB4—parotid gland—pharynx cancer	0.00268	0.00494	CbGeAlD
Dasatinib—KIT—mouth—pharynx cancer	0.00267	0.00492	CbGeAlD
Dasatinib—MAPK14—brainstem—pharynx cancer	0.00265	0.00489	CbGeAlD
Dasatinib—RIPK2—epithelium—pharynx cancer	0.00265	0.00489	CbGeAlD
Dasatinib—LYN—lymphoid tissue—pharynx cancer	0.00264	0.00488	CbGeAlD
Dasatinib—EPHA2—parotid gland—pharynx cancer	0.00263	0.00485	CbGeAlD
Dasatinib—LIMK2—trachea—pharynx cancer	0.00262	0.00484	CbGeAlD
Dasatinib—STAT5B—head—pharynx cancer	0.00262	0.00483	CbGeAlD
Dasatinib—BTK—lymphoid tissue—pharynx cancer	0.00259	0.00478	CbGeAlD
Dasatinib—EPHB4—saliva-secreting gland—pharynx cancer	0.00257	0.00473	CbGeAlD
Dasatinib—MAP3K3—parotid gland—pharynx cancer	0.00256	0.00473	CbGeAlD
Dasatinib—MAP4K5—parotid gland—pharynx cancer	0.00256	0.00473	CbGeAlD
Dasatinib—ERBB3—epithelium—pharynx cancer	0.00254	0.00468	CbGeAlD
Dasatinib—CSK—trachea—pharynx cancer	0.00252	0.00466	CbGeAlD
Dasatinib—EPHA2—saliva-secreting gland—pharynx cancer	0.00252	0.00464	CbGeAlD
Dasatinib—HCK—trachea—pharynx cancer	0.00249	0.0046	CbGeAlD
Dasatinib—FYN—brainstem—pharynx cancer	0.00246	0.00454	CbGeAlD
Dasatinib—EPHB1—lymph node—pharynx cancer	0.00246	0.00454	CbGeAlD
Dasatinib—MAP4K5—saliva-secreting gland—pharynx cancer	0.00246	0.00453	CbGeAlD
Dasatinib—MAP3K3—saliva-secreting gland—pharynx cancer	0.00246	0.00453	CbGeAlD
Dasatinib—EPHB6—parotid gland—pharynx cancer	0.00245	0.00452	CbGeAlD
Dasatinib—EPHA3—head—pharynx cancer	0.00242	0.00446	CbGeAlD
Dasatinib—EPHA5—spinal cord—pharynx cancer	0.00241	0.00444	CbGeAlD
Dasatinib—YES1—parotid gland—pharynx cancer	0.00237	0.00437	CbGeAlD
Dasatinib—MAPK14—epithelium—pharynx cancer	0.00236	0.00436	CbGeAlD
Dasatinib—SIK3—head—pharynx cancer	0.00235	0.00434	CbGeAlD
Dasatinib—BTK—spinal cord—pharynx cancer	0.00235	0.00433	CbGeAlD
Dasatinib—EPHB6—saliva-secreting gland—pharynx cancer	0.00235	0.00433	CbGeAlD
Dasatinib—RIPK2—trachea—pharynx cancer	0.00234	0.00432	CbGeAlD
Dasatinib—LIMK2—lymphoid tissue—pharynx cancer	0.00228	0.00421	CbGeAlD
Dasatinib—KIT—neck—pharynx cancer	0.00228	0.00421	CbGeAlD
Dasatinib—YES1—saliva-secreting gland—pharynx cancer	0.00227	0.00418	CbGeAlD
Dasatinib—EPHA4—trachea—pharynx cancer	0.00226	0.00418	CbGeAlD
Dasatinib—ERBB3—trachea—pharynx cancer	0.00224	0.00414	CbGeAlD
Dasatinib—EPHB4—epithelium—pharynx cancer	0.00224	0.00413	CbGeAlD
Dasatinib—PDGFRB—neck—pharynx cancer	0.00223	0.00411	CbGeAlD
Dasatinib—JAK2—epithelium—pharynx cancer	0.00222	0.0041	CbGeAlD
Dasatinib—CSK—lymphoid tissue—pharynx cancer	0.0022	0.00406	CbGeAlD
Dasatinib—EPHA2—epithelium—pharynx cancer	0.0022	0.00405	CbGeAlD
Dasatinib—ZAK—head—pharynx cancer	0.00219	0.00404	CbGeAlD
Dasatinib—TESK1—spinal cord—pharynx cancer	0.00218	0.00401	CbGeAlD
Dasatinib—HCK—lymphoid tissue—pharynx cancer	0.00217	0.004	CbGeAlD
Dasatinib—EPHB3—spinal cord—pharynx cancer	0.00214	0.00395	CbGeAlD
Dasatinib—EPHA5—head—pharynx cancer	0.00214	0.00395	CbGeAlD
Dasatinib—LYN—head—pharynx cancer	0.00213	0.00393	CbGeAlD
Dasatinib—MAP3K19—head—pharynx cancer	0.0021	0.00387	CbGeAlD
Dasatinib—BMPR1B—head—pharynx cancer	0.0021	0.00387	CbGeAlD
Dasatinib—MAP2K5—parotid gland—pharynx cancer	0.0021	0.00387	CbGeAlD
Dasatinib—LCK—trachea—pharynx cancer	0.00208	0.00384	CbGeAlD
Dasatinib—LIMK2—spinal cord—pharynx cancer	0.00207	0.00382	CbGeAlD
Dasatinib—BMX—lymph node—pharynx cancer	0.00207	0.00382	CbGeAlD
Dasatinib—TNK2—head—pharynx cancer	0.00206	0.00379	CbGeAlD
Dasatinib—BLK—lymph node—pharynx cancer	0.00204	0.00377	CbGeAlD
Dasatinib—MAP2K5—saliva-secreting gland—pharynx cancer	0.00201	0.0037	CbGeAlD
Dasatinib—CSK—spinal cord—pharynx cancer	0.00199	0.00368	CbGeAlD
Dasatinib—SIK1—lymphoid tissue—pharynx cancer	0.00199	0.00368	CbGeAlD
Dasatinib—EPHB4—trachea—pharynx cancer	0.00198	0.00365	CbGeAlD
Dasatinib—HCK—spinal cord—pharynx cancer	0.00197	0.00363	CbGeAlD
Dasatinib—MAP2K5—brainstem—pharynx cancer	0.00197	0.00363	CbGeAlD
Dasatinib—JAK2—trachea—pharynx cancer	0.00197	0.00363	CbGeAlD
Dasatinib—TXK—lymph node—pharynx cancer	0.00196	0.00361	CbGeAlD
Dasatinib—ERBB3—lymphoid tissue—pharynx cancer	0.00195	0.0036	CbGeAlD
Dasatinib—EPHA2—trachea—pharynx cancer	0.00194	0.00358	CbGeAlD
Dasatinib—FYN—trachea—pharynx cancer	0.00194	0.00358	CbGeAlD
Dasatinib—MAP3K2—lymphoid tissue—pharynx cancer	0.00193	0.00357	CbGeAlD
Dasatinib—TESK1—head—pharynx cancer	0.00193	0.00357	CbGeAlD
Dasatinib—SRC—epithelium—pharynx cancer	0.0019	0.00351	CbGeAlD
Dasatinib—STK36—head—pharynx cancer	0.0019	0.00351	CbGeAlD
Dasatinib—EPHB3—head—pharynx cancer	0.0019	0.00351	CbGeAlD
Dasatinib—MAP4K5—trachea—pharynx cancer	0.00189	0.0035	CbGeAlD
Dasatinib—MAP3K3—trachea—pharynx cancer	0.00189	0.0035	CbGeAlD
Dasatinib—KIT—parotid gland—pharynx cancer	0.00186	0.00343	CbGeAlD
Dasatinib—RIPK2—spinal cord—pharynx cancer	0.00185	0.00341	CbGeAlD
Dasatinib—LIMK2—head—pharynx cancer	0.00184	0.00339	CbGeAlD
Dasatinib—STAT5B—lymph node—pharynx cancer	0.00183	0.00338	CbGeAlD
Dasatinib—MAPK14—lymphoid tissue—pharynx cancer	0.00182	0.00336	CbGeAlD
Dasatinib—PDGFRB—parotid gland—pharynx cancer	0.00181	0.00335	CbGeAlD
Dasatinib—FGR—lymphoid tissue—pharynx cancer	0.00181	0.00334	CbGeAlD
Dasatinib—EPHB6—trachea—pharynx cancer	0.00181	0.00334	CbGeAlD
Dasatinib—SIK1—spinal cord—pharynx cancer	0.00181	0.00333	CbGeAlD
Dasatinib—STK35—head—pharynx cancer	0.00178	0.00329	CbGeAlD
Dasatinib—KIT—saliva-secreting gland—pharynx cancer	0.00178	0.00328	CbGeAlD
Dasatinib—CSK—head—pharynx cancer	0.00177	0.00327	CbGeAlD
Dasatinib—ERBB3—spinal cord—pharynx cancer	0.00177	0.00327	CbGeAlD
Dasatinib—YES1—trachea—pharynx cancer	0.00175	0.00323	CbGeAlD
Dasatinib—HCK—head—pharynx cancer	0.00175	0.00323	CbGeAlD
Dasatinib—KIT—brainstem—pharynx cancer	0.00174	0.00321	CbGeAlD
Dasatinib—PDGFRB—saliva-secreting gland—pharynx cancer	0.00174	0.00321	CbGeAlD
Dasatinib—PDGFRA—trachea—pharynx cancer	0.00172	0.00317	CbGeAlD
Dasatinib—JAK2—lymphoid tissue—pharynx cancer	0.00171	0.00316	CbGeAlD
Dasatinib—EPHA3—lymph node—pharynx cancer	0.00169	0.00312	CbGeAlD
Dasatinib—EPHA2—lymphoid tissue—pharynx cancer	0.00169	0.00312	CbGeAlD
Dasatinib—FYN—lymphoid tissue—pharynx cancer	0.00169	0.00312	CbGeAlD
Dasatinib—MAP4K5—lymphoid tissue—pharynx cancer	0.00165	0.00304	CbGeAlD
Dasatinib—MAPK14—spinal cord—pharynx cancer	0.00165	0.00304	CbGeAlD
Dasatinib—SIK3—lymph node—pharynx cancer	0.00165	0.00304	CbGeAlD
Dasatinib—RIPK2—head—pharynx cancer	0.00164	0.00303	CbGeAlD
Dasatinib—ABL1—parotid gland—pharynx cancer	0.00162	0.00298	CbGeAlD
Dasatinib—SIK1—head—pharynx cancer	0.00161	0.00296	CbGeAlD
Dasatinib—EPHA4—head—pharynx cancer	0.00159	0.00293	CbGeAlD
Dasatinib—ERBB3—head—pharynx cancer	0.00157	0.0029	CbGeAlD
Dasatinib—EPHB4—spinal cord—pharynx cancer	0.00156	0.00288	CbGeAlD
Dasatinib—MAP3K2—head—pharynx cancer	0.00156	0.00288	CbGeAlD
Dasatinib—JAK2—spinal cord—pharynx cancer	0.00155	0.00286	CbGeAlD
Dasatinib—KIT—epithelium—pharynx cancer	0.00155	0.00286	CbGeAlD
Dasatinib—ABL1—saliva-secreting gland—pharynx cancer	0.00155	0.00286	CbGeAlD
Dasatinib—MAP2K5—trachea—pharynx cancer	0.00155	0.00286	CbGeAlD
Dasatinib—ZAK—lymph node—pharynx cancer	0.00153	0.00283	CbGeAlD
Dasatinib—FYN—spinal cord—pharynx cancer	0.00153	0.00282	CbGeAlD
Dasatinib—YES1—lymphoid tissue—pharynx cancer	0.00152	0.00281	CbGeAlD
Dasatinib—ABL1—brainstem—pharynx cancer	0.00152	0.0028	CbGeAlD
Dasatinib—PDGFRB—epithelium—pharynx cancer	0.00152	0.0028	CbGeAlD
Dasatinib—CSF1R—trachea—pharynx cancer	0.00151	0.00279	CbGeAlD
Dasatinib—MAP4K5—spinal cord—pharynx cancer	0.0015	0.00276	CbGeAlD
Dasatinib—MAP3K3—spinal cord—pharynx cancer	0.0015	0.00276	CbGeAlD
Dasatinib—PDGFRA—lymphoid tissue—pharynx cancer	0.00149	0.00276	CbGeAlD
Dasatinib—BMPR1B—lymph node—pharynx cancer	0.00147	0.00271	CbGeAlD
Dasatinib—SRC—lymphoid tissue—pharynx cancer	0.00147	0.0027	CbGeAlD
Dasatinib—MAPK14—head—pharynx cancer	0.00147	0.0027	CbGeAlD
Dasatinib—BTK—lymph node—pharynx cancer	0.00146	0.0027	CbGeAlD
Dasatinib—FGR—head—pharynx cancer	0.00146	0.00269	CbGeAlD
Dasatinib—TNK2—lymph node—pharynx cancer	0.00144	0.00266	CbGeAlD
Dasatinib—EPHB6—spinal cord—pharynx cancer	0.00143	0.00264	CbGeAlD
Dasatinib—FMO3—head—pharynx cancer	0.00141	0.0026	CbGeAlD
Dasatinib—CYP1A1—mouth—pharynx cancer	0.00139	0.00256	CbGeAlD
Dasatinib—YES1—spinal cord—pharynx cancer	0.00138	0.00255	CbGeAlD
Dasatinib—JAK2—head—pharynx cancer	0.00138	0.00254	CbGeAlD
Dasatinib—KIT—trachea—pharynx cancer	0.00137	0.00253	CbGeAlD
Dasatinib—EPHA2—head—pharynx cancer	0.00136	0.00251	CbGeAlD
Dasatinib—FYN—head—pharynx cancer	0.00136	0.00251	CbGeAlD
Dasatinib—PDGFRA—spinal cord—pharynx cancer	0.00136	0.0025	CbGeAlD
Dasatinib—TESK1—lymph node—pharynx cancer	0.00135	0.0025	CbGeAlD
Dasatinib—PDGFRB—trachea—pharynx cancer	0.00134	0.00247	CbGeAlD
Dasatinib—STK36—lymph node—pharynx cancer	0.00133	0.00246	CbGeAlD
Dasatinib—EPHB3—lymph node—pharynx cancer	0.00133	0.00246	CbGeAlD
Dasatinib—MAP4K5—head—pharynx cancer	0.00133	0.00245	CbGeAlD
Dasatinib—MAP3K3—head—pharynx cancer	0.00133	0.00245	CbGeAlD
Dasatinib—SRC—spinal cord—pharynx cancer	0.00133	0.00245	CbGeAlD
Dasatinib—CSF1R—lymphoid tissue—pharynx cancer	0.00132	0.00243	CbGeAlD
Dasatinib—LIMK2—lymph node—pharynx cancer	0.00129	0.00238	CbGeAlD
Dasatinib—EPHB6—head—pharynx cancer	0.00127	0.00234	CbGeAlD
Dasatinib—STK35—lymph node—pharynx cancer	0.00125	0.0023	CbGeAlD
Dasatinib—CSK—lymph node—pharynx cancer	0.00124	0.00229	CbGeAlD
Dasatinib—YES1—head—pharynx cancer	0.00123	0.00227	CbGeAlD
Dasatinib—HCK—lymph node—pharynx cancer	0.00122	0.00226	CbGeAlD
Dasatinib—MAP2K5—spinal cord—pharynx cancer	0.00122	0.00226	CbGeAlD
Dasatinib—ABL2—lymph node—pharynx cancer	0.00122	0.00224	CbGeAlD
Dasatinib—PDGFRA—head—pharynx cancer	0.0012	0.00222	CbGeAlD
Dasatinib—KIT—lymphoid tissue—pharynx cancer	0.00119	0.0022	CbGeAlD
Dasatinib—ABL1—trachea—pharynx cancer	0.00119	0.0022	CbGeAlD
Dasatinib—CSF1R—spinal cord—pharynx cancer	0.00119	0.0022	CbGeAlD
Dasatinib—SRC—head—pharynx cancer	0.00118	0.00218	CbGeAlD
Dasatinib—PDGFRB—lymphoid tissue—pharynx cancer	0.00117	0.00215	CbGeAlD
Dasatinib—RIPK2—lymph node—pharynx cancer	0.00115	0.00212	CbGeAlD
Dasatinib—SIK1—lymph node—pharynx cancer	0.00112	0.00207	CbGeAlD
Dasatinib—EPHA4—lymph node—pharynx cancer	0.00111	0.00205	CbGeAlD
Dasatinib—ERBB3—lymph node—pharynx cancer	0.0011	0.00203	CbGeAlD
Dasatinib—MAP3K2—lymph node—pharynx cancer	0.00109	0.00201	CbGeAlD
Dasatinib—MAP2K5—head—pharynx cancer	0.00109	0.002	CbGeAlD
Dasatinib—KIT—spinal cord—pharynx cancer	0.00108	0.002	CbGeAlD
Dasatinib—CSF1R—head—pharynx cancer	0.00106	0.00196	CbGeAlD
Dasatinib—PDGFRB—spinal cord—pharynx cancer	0.00106	0.00195	CbGeAlD
Dasatinib—ABL1—lymphoid tissue—pharynx cancer	0.00104	0.00192	CbGeAlD
Dasatinib—MAPK14—lymph node—pharynx cancer	0.00103	0.00189	CbGeAlD
Dasatinib—FGR—lymph node—pharynx cancer	0.00102	0.00189	CbGeAlD
Dasatinib—LCK—lymph node—pharynx cancer	0.00102	0.00189	CbGeAlD
Dasatinib—ABCG2—parotid gland—pharynx cancer	0.00102	0.00188	CbGeAlD
Dasatinib—FMO3—lymph node—pharynx cancer	0.000987	0.00182	CbGeAlD
Dasatinib—ABCG2—saliva-secreting gland—pharynx cancer	0.000976	0.0018	CbGeAlD
Dasatinib—EPHB4—lymph node—pharynx cancer	0.000973	0.00179	CbGeAlD
Dasatinib—CYP1A1—parotid gland—pharynx cancer	0.000968	0.00179	CbGeAlD
Dasatinib—JAK2—lymph node—pharynx cancer	0.000966	0.00178	CbGeAlD
Dasatinib—KIT—head—pharynx cancer	0.000963	0.00178	CbGeAlD
Dasatinib—EPHA2—lymph node—pharynx cancer	0.000954	0.00176	CbGeAlD
Dasatinib—FYN—lymph node—pharynx cancer	0.000953	0.00176	CbGeAlD
Dasatinib—ABL1—spinal cord—pharynx cancer	0.000943	0.00174	CbGeAlD
Dasatinib—PDGFRB—head—pharynx cancer	0.00094	0.00174	CbGeAlD
Dasatinib—MAP4K5—lymph node—pharynx cancer	0.000931	0.00172	CbGeAlD
Dasatinib—MAP3K3—lymph node—pharynx cancer	0.000931	0.00172	CbGeAlD
Dasatinib—EPHB6—lymph node—pharynx cancer	0.00089	0.00164	CbGeAlD
Dasatinib—CYP1B1—lymphoid tissue—pharynx cancer	0.000881	0.00163	CbGeAlD
Dasatinib—YES1—lymph node—pharynx cancer	0.00086	0.00159	CbGeAlD
Dasatinib—PDGFRA—lymph node—pharynx cancer	0.000843	0.00156	CbGeAlD
Dasatinib—ABL1—head—pharynx cancer	0.000838	0.00155	CbGeAlD
Dasatinib—SRC—lymph node—pharynx cancer	0.000827	0.00153	CbGeAlD
Dasatinib—CYP1A1—epithelium—pharynx cancer	0.000809	0.00149	CbGeAlD
Dasatinib—MAP2K5—lymph node—pharynx cancer	0.000761	0.0014	CbGeAlD
Dasatinib—CSF1R—lymph node—pharynx cancer	0.000743	0.00137	CbGeAlD
Dasatinib—CYP1A1—trachea—pharynx cancer	0.000715	0.00132	CbGeAlD
Dasatinib—CYP1B1—head—pharynx cancer	0.00071	0.00131	CbGeAlD
Dasatinib—KIT—lymph node—pharynx cancer	0.000674	0.00124	CbGeAlD
Dasatinib—PDGFRB—lymph node—pharynx cancer	0.000659	0.00121	CbGeAlD
Dasatinib—ABCG2—spinal cord—pharynx cancer	0.000595	0.0011	CbGeAlD
Dasatinib—ABL1—lymph node—pharynx cancer	0.000587	0.00108	CbGeAlD
Dasatinib—CYP1A1—head—pharynx cancer	0.000502	0.000926	CbGeAlD
Dasatinib—CYP1B1—lymph node—pharynx cancer	0.000497	0.000917	CbGeAlD
Dasatinib—ABCB1—epithelium—pharynx cancer	0.00042	0.000775	CbGeAlD
Dasatinib—ABCB1—trachea—pharynx cancer	0.000371	0.000685	CbGeAlD
Dasatinib—ABCG2—lymph node—pharynx cancer	0.00037	0.000683	CbGeAlD
Dasatinib—CYP1A1—lymph node—pharynx cancer	0.000351	0.000648	CbGeAlD
Dasatinib—ABCB1—lymphoid tissue—pharynx cancer	0.000323	0.000597	CbGeAlD
Dasatinib—ABCB1—spinal cord—pharynx cancer	0.000293	0.000541	CbGeAlD
Dasatinib—ABCB1—head—pharynx cancer	0.000261	0.000481	CbGeAlD
Dasatinib—ABCB1—lymph node—pharynx cancer	0.000183	0.000337	CbGeAlD
Dasatinib—FYN—B Cell Activation—EGFR—pharynx cancer	0.000174	0.000379	CbGpPWpGaD
Dasatinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000173	0.000377	CbGpPWpGaD
Dasatinib—STAT5B—Immune System—CDH1—pharynx cancer	0.000171	0.000374	CbGpPWpGaD
Dasatinib—PDGFRA—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000171	0.000373	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—ADH1B—pharynx cancer	0.000171	0.000373	CbGpPWpGaD
Dasatinib—CSK—Adaptive Immune System—EGFR—pharynx cancer	0.000171	0.000373	CbGpPWpGaD
Dasatinib—PDGFRB—MAPK Signaling Pathway—TP53—pharynx cancer	0.000171	0.000372	CbGpPWpGaD
Dasatinib—MAPK14—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.00017	0.000372	CbGpPWpGaD
Dasatinib—LCK—Downstream signal transduction—EGFR—pharynx cancer	0.000169	0.000368	CbGpPWpGaD
Dasatinib—LCK—Signaling by FGFR—EGFR—pharynx cancer	0.000168	0.000366	CbGpPWpGaD
Dasatinib—LCK—Signaling by ERBB2—EGFR—pharynx cancer	0.000167	0.000365	CbGpPWpGaD
Dasatinib—SRC—Focal Adhesion—CCND1—pharynx cancer	0.000167	0.000364	CbGpPWpGaD
Dasatinib—FYN—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000166	0.000363	CbGpPWpGaD
Dasatinib—LCK—DAP12 signaling—EGFR—pharynx cancer	0.000166	0.000363	CbGpPWpGaD
Dasatinib—SRC—Signaling by SCF-KIT—EGFR—pharynx cancer	0.000166	0.000363	CbGpPWpGaD
Dasatinib—SRC—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	0.000166	0.000362	CbGpPWpGaD
Dasatinib—CSK—Hemostasis—TP53—pharynx cancer	0.000166	0.000362	CbGpPWpGaD
Dasatinib—TXK—Immune System—EGFR—pharynx cancer	0.000165	0.00036	CbGpPWpGaD
Dasatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—EGFR—pharynx cancer	0.000164	0.000358	CbGpPWpGaD
Dasatinib—YES1—Adaptive Immune System—CDH1—pharynx cancer	0.000163	0.000356	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—B4GALT5—pharynx cancer	0.000163	0.000356	CbGpPWpGaD
Dasatinib—SRC—Disease—B4GALT5—pharynx cancer	0.000162	0.000354	CbGpPWpGaD
Dasatinib—MAPK14—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.00016	0.00035	CbGpPWpGaD
Dasatinib—KIT—Immune System—CD79A—pharynx cancer	0.000159	0.000347	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—CD79A—pharynx cancer	0.000159	0.000346	CbGpPWpGaD
Dasatinib—MAPK14—MAPK Signaling Pathway—TP53—pharynx cancer	0.000158	0.000346	CbGpPWpGaD
Dasatinib—JAK2—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000158	0.000345	CbGpPWpGaD
Dasatinib—YES1—Axon guidance—EGFR—pharynx cancer	0.000158	0.000344	CbGpPWpGaD
Dasatinib—LCK—Fc epsilon receptor (FCERI) signaling—EGFR—pharynx cancer	0.000156	0.000341	CbGpPWpGaD
Dasatinib—LCK—DAP12 interactions—EGFR—pharynx cancer	0.000156	0.000341	CbGpPWpGaD
Dasatinib—LCK—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000156	0.000341	CbGpPWpGaD
Dasatinib—KIT—Signaling by NGF—EGFR—pharynx cancer	0.000156	0.00034	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—ADH1B—pharynx cancer	0.000155	0.000339	CbGpPWpGaD
Dasatinib—LCK—Signaling by EGFR—EGFR—pharynx cancer	0.000155	0.000338	CbGpPWpGaD
Dasatinib—LCK—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000154	0.000335	CbGpPWpGaD
Dasatinib—LCK—Signaling by PDGF—EGFR—pharynx cancer	0.000153	0.000334	CbGpPWpGaD
Dasatinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pharynx cancer	0.000153	0.000334	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—CDH1—pharynx cancer	0.000152	0.000332	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—CD79A—pharynx cancer	0.00015	0.000328	CbGpPWpGaD
Dasatinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.00015	0.000328	CbGpPWpGaD
Dasatinib—SRC—Downstream signal transduction—EGFR—pharynx cancer	0.000149	0.000326	CbGpPWpGaD
Dasatinib—BTK—Innate Immune System—EGFR—pharynx cancer	0.000149	0.000324	CbGpPWpGaD
Dasatinib—SRC—Signaling by FGFR—EGFR—pharynx cancer	0.000149	0.000324	CbGpPWpGaD
Dasatinib—SRC—EGF/EGFR Signaling Pathway—EGFR—pharynx cancer	0.000149	0.000324	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—B4GALT5—pharynx cancer	0.000148	0.000324	CbGpPWpGaD
Dasatinib—BTK—Immune System—CDH1—pharynx cancer	0.000148	0.000323	CbGpPWpGaD
Dasatinib—SRC—Signaling by ERBB2—EGFR—pharynx cancer	0.000148	0.000323	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling by NGF—EGFR—pharynx cancer	0.000147	0.000322	CbGpPWpGaD
Dasatinib—SRC—TGF-beta Signaling Pathway—TP53—pharynx cancer	0.000147	0.000321	CbGpPWpGaD
Dasatinib—MAPK14—Cellular Senescence—TP53—pharynx cancer	0.000146	0.000319	CbGpPWpGaD
Dasatinib—KIT—Adaptive Immune System—CDH1—pharynx cancer	0.000146	0.000318	CbGpPWpGaD
Dasatinib—LCK—B Cell Activation—EGFR—pharynx cancer	0.000145	0.000316	CbGpPWpGaD
Dasatinib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000143	0.000312	CbGpPWpGaD
Dasatinib—BTK—Adaptive Immune System—EGFR—pharynx cancer	0.000143	0.000312	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CNDP2—pharynx cancer	0.00014	0.000307	CbGpPWpGaD
Dasatinib—LCK—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000138	0.000302	CbGpPWpGaD
Dasatinib—SRC—Signaling by FGFR in disease—EGFR—pharynx cancer	0.000138	0.000302	CbGpPWpGaD
Dasatinib—PDGFRA—Adaptive Immune System—CDH1—pharynx cancer	0.000138	0.000301	CbGpPWpGaD
Dasatinib—SRC—Signaling by EGFR—EGFR—pharynx cancer	0.000137	0.0003	CbGpPWpGaD
Dasatinib—HCK—Innate Immune System—EGFR—pharynx cancer	0.000136	0.000298	CbGpPWpGaD
Dasatinib—SRC—Signaling by EGFR in Cancer—EGFR—pharynx cancer	0.000136	0.000297	CbGpPWpGaD
Dasatinib—HCK—Immune System—CDH1—pharynx cancer	0.000136	0.000297	CbGpPWpGaD
Dasatinib—SRC—Signaling by PDGF—EGFR—pharynx cancer	0.000135	0.000296	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—CD79A—pharynx cancer	0.000135	0.000296	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling by NGF—EGFR—pharynx cancer	0.000133	0.00029	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CNDP2—pharynx cancer	0.000133	0.00029	CbGpPWpGaD
Dasatinib—LYN—Immune System—CD79A—pharynx cancer	0.000133	0.000289	CbGpPWpGaD
Dasatinib—ABL1—Immune System—CD79A—pharynx cancer	0.000132	0.000288	CbGpPWpGaD
Dasatinib—SRC—Focal Adhesion—EGFR—pharynx cancer	0.000131	0.000286	CbGpPWpGaD
Dasatinib—FYN—Immune System—CD79A—pharynx cancer	0.00013	0.000285	CbGpPWpGaD
Dasatinib—SRC—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	0.00013	0.000284	CbGpPWpGaD
Dasatinib—RIPK2—Innate Immune System—EGFR—pharynx cancer	0.000128	0.00028	CbGpPWpGaD
Dasatinib—FYN—Signaling by NGF—EGFR—pharynx cancer	0.000128	0.000279	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—CDH1—pharynx cancer	0.000128	0.000279	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ADH7—pharynx cancer	0.000127	0.000277	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CD79A—pharynx cancer	0.000126	0.000274	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—CDH1—pharynx cancer	0.000124	0.000271	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CD79A—pharynx cancer	0.000124	0.000271	CbGpPWpGaD
Dasatinib—RIPK2—Adaptive Immune System—EGFR—pharynx cancer	0.000123	0.000269	CbGpPWpGaD
Dasatinib—MAPK14—Signaling by NGF—EGFR—pharynx cancer	0.000123	0.000269	CbGpPWpGaD
Dasatinib—FGR—Innate Immune System—EGFR—pharynx cancer	0.000123	0.000269	CbGpPWpGaD
Dasatinib—BLK—Immune System—CDH1—pharynx cancer	0.000123	0.000269	CbGpPWpGaD
Dasatinib—FGR—Immune System—CDH1—pharynx cancer	0.000123	0.000268	CbGpPWpGaD
Dasatinib—SRC—NGF signalling via TRKA from the plasma membrane—EGFR—pharynx cancer	0.000123	0.000268	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—CDH1—pharynx cancer	0.000122	0.000266	CbGpPWpGaD
Dasatinib—JAK2—Signaling by NGF—EGFR—pharynx cancer	0.000122	0.000266	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—CCND1—pharynx cancer	0.000121	0.000264	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ADH7—pharynx cancer	0.00012	0.000262	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—CDH1—pharynx cancer	0.00012	0.000262	CbGpPWpGaD
Dasatinib—BLK—Adaptive Immune System—EGFR—pharynx cancer	0.000119	0.000259	CbGpPWpGaD
Dasatinib—LYN—Axon guidance—EGFR—pharynx cancer	0.000118	0.000257	CbGpPWpGaD
Dasatinib—ABL1—Axon guidance—EGFR—pharynx cancer	0.000117	0.000256	CbGpPWpGaD
Dasatinib—FYN—Axon guidance—EGFR—pharynx cancer	0.000116	0.000253	CbGpPWpGaD
Dasatinib—FGR—Hemostasis—TP53—pharynx cancer	0.000115	0.000251	CbGpPWpGaD
Dasatinib—ERBB3—Innate Immune System—EGFR—pharynx cancer	0.000113	0.000247	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—CDH1—pharynx cancer	0.000113	0.000246	CbGpPWpGaD
Dasatinib—YES1—Developmental Biology—EGFR—pharynx cancer	0.000113	0.000246	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ADH1B—pharynx cancer	0.000111	0.000243	CbGpPWpGaD
Dasatinib—MAPK14—Cellular responses to stress—TP53—pharynx cancer	0.00011	0.000241	CbGpPWpGaD
Dasatinib—JAK2—Axon guidance—EGFR—pharynx cancer	0.00011	0.00024	CbGpPWpGaD
Dasatinib—SRC—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	0.000109	0.000239	CbGpPWpGaD
Dasatinib—ERBB3—Adaptive Immune System—EGFR—pharynx cancer	0.000109	0.000237	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD79A—pharynx cancer	0.000109	0.000237	CbGpPWpGaD
Dasatinib—LCK—Signaling by NGF—EGFR—pharynx cancer	0.000107	0.000233	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—B4GALT5—pharynx cancer	0.000106	0.000232	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CNDP2—pharynx cancer	0.000106	0.000231	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ADH1B—pharynx cancer	0.000105	0.00023	CbGpPWpGaD
Dasatinib—CSK—Immune System—EGFR—pharynx cancer	0.000103	0.000226	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—B4GALT5—pharynx cancer	0.000101	0.000219	CbGpPWpGaD
Dasatinib—STAT5B—Immune System—EGFR—pharynx cancer	0.0001	0.000219	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—CDH1—pharynx cancer	9.98e-05	0.000218	CbGpPWpGaD
Dasatinib—YES1—Innate Immune System—EGFR—pharynx cancer	9.94e-05	0.000217	CbGpPWpGaD
Dasatinib—YES1—Immune System—CDH1—pharynx cancer	9.9e-05	0.000216	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—pharynx cancer	9.82e-05	0.000214	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD79A—pharynx cancer	9.62e-05	0.00021	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ADH7—pharynx cancer	9.58e-05	0.000209	CbGpPWpGaD
Dasatinib—CSK—Disease—EGFR—pharynx cancer	9.55e-05	0.000209	CbGpPWpGaD
Dasatinib—YES1—Adaptive Immune System—EGFR—pharynx cancer	9.55e-05	0.000208	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—EGFR—pharynx cancer	9.5e-05	0.000207	CbGpPWpGaD
Dasatinib—SRC—Signaling by NGF—EGFR—pharynx cancer	9.43e-05	0.000206	CbGpPWpGaD
Dasatinib—YES1—Hemostasis—TP53—pharynx cancer	9.27e-05	0.000202	CbGpPWpGaD
Dasatinib—STAT5B—Disease—EGFR—pharynx cancer	9.25e-05	0.000202	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—EGFR—pharynx cancer	8.9e-05	0.000194	CbGpPWpGaD
Dasatinib—KIT—Innate Immune System—EGFR—pharynx cancer	8.88e-05	0.000194	CbGpPWpGaD
Dasatinib—KIT—Immune System—CDH1—pharynx cancer	8.84e-05	0.000193	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—CDH1—pharynx cancer	8.83e-05	0.000193	CbGpPWpGaD
Dasatinib—BTK—Immune System—EGFR—pharynx cancer	8.66e-05	0.000189	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—EGFR—pharynx cancer	8.53e-05	0.000186	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—CCND1—pharynx cancer	8.53e-05	0.000186	CbGpPWpGaD
Dasatinib—KIT—Adaptive Immune System—EGFR—pharynx cancer	8.52e-05	0.000186	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CNDP2—pharynx cancer	8.46e-05	0.000185	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—EGFR—pharynx cancer	8.4e-05	0.000183	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ADH1B—pharynx cancer	8.4e-05	0.000183	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—EGFR—pharynx cancer	8.39e-05	0.000183	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—CDH1—pharynx cancer	8.37e-05	0.000183	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—EGFR—pharynx cancer	8.35e-05	0.000182	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—EGFR—pharynx cancer	8.26e-05	0.00018	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—CCND1—pharynx cancer	8.26e-05	0.00018	CbGpPWpGaD
Dasatinib—PDGFRA—Adaptive Immune System—EGFR—pharynx cancer	8.07e-05	0.000176	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—B4GALT5—pharynx cancer	8.03e-05	0.000175	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—TP53—pharynx cancer	7.97e-05	0.000174	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—EGFR—pharynx cancer	7.96e-05	0.000174	CbGpPWpGaD
Dasatinib—HCK—Immune System—EGFR—pharynx cancer	7.94e-05	0.000173	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—EGFR—pharynx cancer	7.85e-05	0.000171	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pharynx cancer	7.71e-05	0.000168	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ADH7—pharynx cancer	7.65e-05	0.000167	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—EGFR—pharynx cancer	7.57e-05	0.000165	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—CDH1—pharynx cancer	7.54e-05	0.000165	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—EGFR—pharynx cancer	7.48e-05	0.000163	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—EGFR—pharynx cancer	7.41e-05	0.000162	CbGpPWpGaD
Dasatinib—LYN—Immune System—CDH1—pharynx cancer	7.38e-05	0.000161	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—EGFR—pharynx cancer	7.38e-05	0.000161	CbGpPWpGaD
Dasatinib—ABL1—Immune System—CDH1—pharynx cancer	7.35e-05	0.00016	CbGpPWpGaD
Dasatinib—HCK—Disease—EGFR—pharynx cancer	7.33e-05	0.00016	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—EGFR—pharynx cancer	7.3e-05	0.000159	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—EGFR—pharynx cancer	7.27e-05	0.000159	CbGpPWpGaD
Dasatinib—FYN—Immune System—CDH1—pharynx cancer	7.27e-05	0.000159	CbGpPWpGaD
Dasatinib—BLK—Immune System—EGFR—pharynx cancer	7.2e-05	0.000157	CbGpPWpGaD
Dasatinib—FGR—Immune System—EGFR—pharynx cancer	7.17e-05	0.000157	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—EGFR—pharynx cancer	7.12e-05	0.000155	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—EGFR—pharynx cancer	7.03e-05	0.000153	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—EGFR—pharynx cancer	7.01e-05	0.000153	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CDH1—pharynx cancer	7e-05	0.000153	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—EGFR—pharynx cancer	6.94e-05	0.000151	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—TP53—pharynx cancer	6.91e-05	0.000151	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CDH1—pharynx cancer	6.91e-05	0.000151	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—TP53—pharynx cancer	6.88e-05	0.00015	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—TP53—pharynx cancer	6.81e-05	0.000149	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ADH1B—pharynx cancer	6.71e-05	0.000146	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—EGFR—pharynx cancer	6.69e-05	0.000146	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—EGFR—pharynx cancer	6.6e-05	0.000144	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—TP53—pharynx cancer	6.55e-05	0.000143	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CNDP2—pharynx cancer	6.53e-05	0.000142	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—EGFR—pharynx cancer	6.48e-05	0.000141	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pharynx cancer	6.47e-05	0.000141	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—TP53—pharynx cancer	6.47e-05	0.000141	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—B4GALT5—pharynx cancer	6.41e-05	0.00014	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—CCND1—pharynx cancer	6.17e-05	0.000135	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—EGFR—pharynx cancer	6.09e-05	0.000133	CbGpPWpGaD
Dasatinib—ERBB3—Disease—EGFR—pharynx cancer	6.09e-05	0.000133	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—EGFR—pharynx cancer	6.08e-05	0.000133	CbGpPWpGaD
Dasatinib—LCK—Immune System—CDH1—pharynx cancer	6.05e-05	0.000132	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ADH7—pharynx cancer	5.9e-05	0.000129	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—EGFR—pharynx cancer	5.83e-05	0.000127	CbGpPWpGaD
Dasatinib—YES1—Immune System—EGFR—pharynx cancer	5.79e-05	0.000126	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—pharynx cancer	5.67e-05	0.000124	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—CCND1—pharynx cancer	5.64e-05	0.000123	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—pharynx cancer	5.62e-05	0.000123	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—pharynx cancer	5.44e-05	0.000119	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—CCND1—pharynx cancer	5.44e-05	0.000119	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—EGFR—pharynx cancer	5.38e-05	0.000117	CbGpPWpGaD
Dasatinib—SRC—Immune System—CDH1—pharynx cancer	5.36e-05	0.000117	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ADH1B—pharynx cancer	5.18e-05	0.000113	CbGpPWpGaD
Dasatinib—KIT—Immune System—EGFR—pharynx cancer	5.17e-05	0.000113	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—EGFR—pharynx cancer	5.16e-05	0.000113	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—pharynx cancer	5.02e-05	0.00011	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—B4GALT5—pharynx cancer	4.95e-05	0.000108	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—EGFR—pharynx cancer	4.89e-05	0.000107	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—EGFR—pharynx cancer	4.84e-05	0.000106	CbGpPWpGaD
Dasatinib—KIT—Disease—EGFR—pharynx cancer	4.77e-05	0.000104	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—CCND1—pharynx cancer	4.77e-05	0.000104	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—EGFR—pharynx cancer	4.52e-05	9.87e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—EGFR—pharynx cancer	4.42e-05	9.66e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—EGFR—pharynx cancer	4.42e-05	9.65e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—EGFR—pharynx cancer	4.41e-05	9.63e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—EGFR—pharynx cancer	4.32e-05	9.43e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—EGFR—pharynx cancer	4.3e-05	9.38e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—EGFR—pharynx cancer	4.26e-05	9.31e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—CCND1—pharynx cancer	4.26e-05	9.3e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—EGFR—pharynx cancer	4.25e-05	9.28e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—EGFR—pharynx cancer	4.09e-05	8.94e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—EGFR—pharynx cancer	4.07e-05	8.89e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—pharynx cancer	4.06e-05	8.87e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—EGFR—pharynx cancer	4.04e-05	8.82e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CCND1—pharynx cancer	4.03e-05	8.81e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—EGFR—pharynx cancer	3.92e-05	8.57e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EGFR—pharynx cancer	3.74e-05	8.17e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—EGFR—pharynx cancer	3.73e-05	8.14e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—pharynx cancer	3.71e-05	8.11e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CCND1—pharynx cancer	3.63e-05	7.93e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—pharynx cancer	3.58e-05	7.82e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CCND1—pharynx cancer	3.56e-05	7.77e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—pharynx cancer	3.54e-05	7.73e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CCND1—pharynx cancer	3.5e-05	7.65e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CCND1—pharynx cancer	3.37e-05	7.36e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—pharynx cancer	3.34e-05	7.3e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CCND1—pharynx cancer	3.33e-05	7.27e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—pharynx cancer	3.27e-05	7.13e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—pharynx cancer	3.16e-05	6.91e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—pharynx cancer	3.14e-05	6.86e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—pharynx cancer	3.13e-05	6.84e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCND1—pharynx cancer	2.92e-05	6.37e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—pharynx cancer	2.89e-05	6.31e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—pharynx cancer	2.85e-05	6.22e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—pharynx cancer	2.81e-05	6.13e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—pharynx cancer	2.79e-05	6.09e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—pharynx cancer	2.75e-05	6e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—pharynx cancer	2.66e-05	5.8e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—pharynx cancer	2.65e-05	5.78e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—pharynx cancer	2.61e-05	5.7e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCND1—pharynx cancer	2.58e-05	5.64e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—pharynx cancer	2.39e-05	5.23e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—pharynx cancer	2.34e-05	5.12e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—pharynx cancer	2.31e-05	5.04e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—pharynx cancer	2.29e-05	5e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—pharynx cancer	2.22e-05	4.85e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—pharynx cancer	2.19e-05	4.79e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—pharynx cancer	2.03e-05	4.42e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—pharynx cancer	1.92e-05	4.19e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—pharynx cancer	1.7e-05	3.71e-05	CbGpPWpGaD
